Story Stocks^®

AngioDynamics (ANGO) is trading sharply higher after delivering a beat and raise Q1 report this morning. The MedTech company, focused on vascular health and cancer therapies, posted modest EPS upside, with revenue also above estimates, increasing 12.1% to $75.7 mln, its second straight quarter of double-digit growth after five consecutive quarters of year-over-year declines.

• Growth was broad-based, with management highlighting Med Tech markets as critical to the company's future. ANGO has reshaped its portfolio to compete in large, faster-growing markets where its technologies can differentiate and capture share.
• Med Tech revenue jumped 26% yr/yr to $35.3 mln, its fourth consecutive quarter of 20%+ growth, driven by standout performances in Auryon atherectomy (+20%), Mechanical Thrombectomy (+41%), and NanoKnife (+27%). Med Device sales increased 2.3% to $40.4 mln.
• Gross margin expanded 90 bps to 55.3%, driven by mix shift toward higher-margin Med Tech products and pricing initiatives, though the company still reported a loss as it continues investing in R&D to support future growth.
• Management struck a particularly bullish tone on long-term growth drivers, pointing to thrombectomy, NanoKnife, and Auryon as areas where it sees significant market share gains and expanding opportunities.
• Guidance was raised early in the fiscal year: FY26 revenue of $308-313 mln (from $305-310 mln), adjusted EBITDA of $6-10 mln (from $3-8 mln), and EPS loss narrowed to $(0.33)-$(0.23) from $(0.35)-$(0.25).

Briefing.com Analyst Insight

This was a strong start to FY26 for ANGO, building on the momentum carried over from late FY25. Its MedTech segment is leading the way, with thrombectomy and NanoKnife adoption continuing to accelerate. While the company is still reporting losses, the early guidance raise and upbeat commentary provide a clear boost in investor sentiment for FY26.